Etiopathogeny, prognosis and therapy of myelodysplastic syndromes

Hematology and Cell Therapy

Volumn 39, Issue 6, 1997, Pages 277-294

  Sanz, G F ^a   Sanz, M A ^a   Vallespi, T ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Etiology; Myelodysplasplatic syndromes; Pathogeny; Prognostic factors; Treatment

Indexed keywords

ALKYLATING AGENT; ANDROGEN; ANTHRACYCLINE ANTIBIOTIC AGENT; BENZENE; CIPROFLOXACIN; CYTARABINE; CYTOTOXIC AGENT; DANAZOL; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIPODOPHYLLOTOXIN DERIVATIVE; ERYTHROPOIETIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; HYDROXYUREA; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOMODULATING AGENT; INTERLEUKIN 3; INTERLEUKIN 6; OXYMETHOLONE; PENTOXIFYLLINE;

ACUTE MYELOBLASTIC LEUKEMIA; AGE; APLASTIC ANEMIA; APOPTOSIS; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; CYTOGENETICS; CYTOPENIA; GENETIC PREDISPOSITION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IONIZING RADIATION; MYELODYSPLASTIC SYNDROME; ONCOGENE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 0031456965     PISSN: 12693286     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00282-997-0277-z     Document Type: Review

References (164)

1. Alessandrino EP, Astori C, Van Lint MT, et al. (1997) Myelodysplastic syndrome or leukemia developing after MDS treated by allogeneic bone marrow transplantation: outcome of 90 adult patients. Leuk Res 21 [Suppl 1]: 52a
2. Anastasi J, Feng J, Le Beau MM, et al. (1993) Cytogenetic donality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion. Blood 81: 1580-1585
3. Anderson D, Hughes JA, Cebulskawasilewska A, et al. (1996) Biological monitoring of workers exposed to emissions from petroleum plants. Environ Health Perspect 104: 609-613
4. Anderson JE, Appelbaum FR, Fisher LD, et al. (1993) Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 82: 677-681
5. Anderson JE, Appelbaum FR, Schoch G, et al. (1996) Allogeneic bone marrow transplantation for myelodysplastic syndromes with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 14: 220-226
6. Anderson JE, Appelbaum FR, Schoch G, et al. (1996) Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood 87: 51-58
7. Anderson JE, Anasetti C, Appelbaum FR, et al. (1996) Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol 93: 59-67
8. Anderson JE, Thomas DE (1997) The Seattle experience with bone marrow transplantation (BMT) for myelodysplasia (MDS) Leuk Res 21 [Suppl 1]: 51a
9. Anderson JE, Gooley TA, Schoch G, et al. (1997). Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 89: 2578-2585
10. Appelbaum FR, Barrall J, Storb R, et al. (1990) Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. Ann Intern Med 112: 590-597
11. Aul C, Gatterman N, Heyll A, Germing U, et al. (1992) Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6: 52-59
12. Aul C, Gattermann N, Schneider W (1995) Epidemiological and etiological aspects of myelodysplastic syndromes. Leuk Lymphoma 16: 247-262
13. Aul C, Runde V, et al. (1997) Aggressive chemotherapy in MDS: the Düsseldorf experience Leuk Res 21 [Suppl 1]: 45a
14. Backs B, Broeders L, Tow I, Löwenberg B (1993) Blast colonyforming cells in myelodysplastic syndrome: decreased potential to generate erythroid precursors. Leukemia 7: 75-79
15. Bader-Meunier B, MielTow I, Löwenberg B (1993) Blast colonyforming cells in myelodysplastic syndrome: decreased potential to generate erythroid precursors. Leukemia 7: 75-7
16. Bartram CR (1996) Molecular genetic aspects of myelodysplastic syndromes. Semin Hematol 33: 139-149
17. Benitez J, Carbonell F, Sanchez-Fayos J, et al. (1985) Karyotypic evolution in patients with myelodysplastic syndromes. Cancer Genet Cytogenet 16: 157-167
18. Bennett JM, Catovsky D, Daniel MT, et al. (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189-199
19. Bennett JM, Moloney WC, Greene MH et al. (1987) Acute myeloid leukemia and other myelopathic disorders following treatment with alkylating agents. Hematol Pathol 1: 99-104
20. Benyehuda D, Krichevsky S, Caspi O, et al. (1996) Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 88: 4296-4303
21. Beran M, Kantarjian H, O'Brien S, et al. (1996) Topotecan, a topoisomerase I inhibitor, is active in the treatment of melodysplastic syndrome and chronic myelomonocytic leukemia. Blood 88: 2473-2479
22. Bernstein SH, Brunetto VL, Davey FR, et al. (1996) Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B study. J Clin Oncol 14: 2486-2494
23. Billström R, Thiede T, Hansen S, et al. (1988) Bone marrow karyotype and prognosis in primary myelodysplastic syndromes. Eur J Haematol 41: 341-346
24. Bishop MR, Iversen PL, Bayever E, et al. (1996) Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol 14: 1320-1326
25. Brusamolino E, Bernasconi C (1992) Therapy-related myelodysplastic syndromes and acute leukemias. Leukemia 6 [Suppl 4]: 23-25
26. Campbell LJ, Garson OM (1994) The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders. Leukemia 8: 67-72
27. Castro-Malaspina H, Schaison G, Passe S, et al. (1984) Subacute and chronic myelomonocytic leukemia in children (juvenile CML). Clinical and hematologic observations and identification of prognostic factors Cancer 54: 675-686
28. Castro-Malaspina H, Childs B, Papadopoulos E, et al. (1997) T-cell depleted (SBA-E) bone marrow transplantation for myelodysplastic syndromes. Leuk Res 21 [Suppl 1]: 51a
29. Catalano L, Selleri C, Montuon N, et al. (1993) Danazol for myelodysplastic syndromes. Br J Haematol 85: 230-231
30. Coiffier B, Adeleine P, Gentilhomme O, et al. (1987) Myelodysplastic syndromes. A multiparametric study of prognostic factors in 336 patients. Cancer 60: 3029-3032
31. Cowles SR, Bennnett JM, Ross CE (1991) Medical surveillance for leukemia at a petrochemical manufacturing complex: four-year summary. J Occup Med 33: 808-812
32. Davies SM, Wagner JE, Defer T, et al. (1997) Unrelated donor bone marrow transplantation for children with aplastic anaemia or myelodysplasia. Br J Haematol 96: 749-756
33. De Witte T, Zwaan F, Hermans J, et al. (1990) Allogeneic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 74: 151-155
34. De Witte T, Gratwohl A (1993) Bone marrow transplantation for myelodysplastic syndromes and secondary leukaemias. Br J Haematol 84: 361-364
35. De Witte T, Suciu S, Peetermans M, et al. (1995) Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS oa more tan 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment of Cancer. Leukemia 9: 1805-1811
36. Del Canizo MC, Sanz G, et al. Chronic myelomonocytic leukemia-clinicobiological characteristics: a multivariate analysis in a series of 70 cases Eur J Haematol 42: 466-473
37. Demuinck H, Delforge M, et al (1996) Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. Br J Haematol 92: 351-359
38. Estey E, Thall P, Anfreef M, et al. (1994) Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12: 671-678
39. Feelman EJ, Seiter KP, Ahmed T, et al. (1996) Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia 10: 40-42
40. Fenaux P, Beuscart R., Lai JL, et al. (1988) Prognostic factors in adult chronic myelomonocytic leukaemia: an analysis of 107 cases. J Clin Oncol 6: 1417-1424
41. Fenaux P, Morel P, Lai JL (1996) Cytogenetics in myelodysplastic syndromes. Semin Hematol 33: 127-138
42. Fenaux P, Wattel E, Solary E, et al. (1997) Intensive therapy with quinine in myelodysplastic syndromes (MDS) Leuk Res 21 [Suppl 1]: 46a
43. Ferrara F, Mirto S, Leoni F, et al. (1997) Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of refractory anemia with excess of blasts in transformation Leuk Res 21 [Suppl 1]: 48a
44. Fonatsch C, Haase D, Freund M, et al. (1991) Partial trisomy 1q. A nonrandom primary chromosomal abnormality in myelodysplastic syndromes? Cancer Genet Cytogenet 56: 243-253
45. Foucar K, Langdon RM, Armitage JO, et al. (1985) Myelodysplastic syndromes: A clinic and pathologic analysis of 109 cases. Cancer 56: 553-561
46. Gallagher A, Darley RL, Padua RA (1997) The molecular basis of myelodysplastic syndromes. Haematologica 82: 191-204
47. Ganser A, Heil G, Hoffmann WK, et al. (1995) Aggressive chemotherapy with idarubicin, Ara-C, VP-16, amsacrin, followed by G-CSF and maintenace immunotherapy with interleukin-2 for advanced myelodysplastic syndromes and high-risk ANLL Blood 86 [Suppl 1]: 434a
48. Ganser A, Hoelzer D (1996) Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. Semin Hematol 33: 186-195
49. Ganser A (1997) Aggressive chemotherapy with G-CSF priming is effective for advanced myelodyspiastic syndromes and high-risk acute myeloid leukaemia: early results. Trends Onco Hematol 5: 3-4
50. Gassmann W, Schmilz N, Löffler H, et al. (1996) Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Semin Hematol 33: 196-205
51. Gattermann N, Aul C, Schneider W (1990) Two types of acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol 74: 45-52
52. Ghaddar HM, Stass SA, Pierce S, et al. (1989) Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol 7: 1637-1645
53. Goasguen JE, Garand R, Bizet M, et al. (1990) Prognostic factors of myelodysplastic syndromes-A simplified 3-D scoring system. Leuk Res 14: 255-260
54. Goldberg H, Lusk E, Moore J, et al. (1990) Survey of exposure to genotoxic agents in primary myelodysplastic syndrome. Correlation with chromosomal patterns and data on patients without hematological disease. Cancer Res 50: 6876-6881
55. Gordon MS, Nemunaitis J, Huffman R, et al. (1995) A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 85: 3066-3076
56. Greenberg P (1992) in vitro marrow culture studies in myelodysplastic syndromes. Semin Oncol 19: 34-46
57. Greenberg P, Taylor K, Larson R, et al. (1993) Phase in randomized multicenter trial of G-CSF versus observation for myelodysplastic syndromes (MDS) Blood 82 [Suppl 1]: 196a
58. Greenberg PL (1996) Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes. Semin Hematol 33: 163-175
59. Greenberg P, Cox C, LeBeau MM, et al. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079-2088
60. Haas OA, Gadner H (1996) Pathogenesis, biology, and management of myelodysplastic syndromes in children. Semin Hematol 33: 225-235
61. Hasle H, Kerndrup G, Yssing M, et al. (1996) Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia. Leukemia 10: 1269-1273
62. Heim S, Mitelman F (1986) Chromosome abnormalities in the myelodysplastic syndromes. Clin Haematol 15: 1003-1021
63. Hellstrom-Lindberg E (1995) The efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 89: 67-71
64. Hellström-Lindberg E, Kanter-Lewensohn L, Öst A (1997) Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res 21: 415-425
65. Hirst WJR, Mufti GJ (1993) Management of myelodysplastic syndromes. Br J Haematol 84: 191-196
66. Hoagland HC, Linman JW (1972) Pyridoxine-responsive anemia: a preleukemic manifestation? Minn Med 55: 891-895
67. Honda Y, Delzell E, Cole P (1995) An updated study of mortality among workers at a petroleum manufacturing plant. J Occup Environ Med 37: 194-200
68. Hurtado R, Sosa R, Majluf A, Labardini JR (1993) Refractory anaemia (RA) type I FAB treated with oxymetholone (OXY): long-term results. Br J Haematol 85: 236-237
69. Ido M, Nagata C, Kawakami N, et al. (1996) A case-control study of myelodysplastic syndromes among Japanese men and women. Leuk Res 20: 727-731
70. Jacobs RH, Cornbleet MA, Vardiman JW, et al. (1986) Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood 67: 1765-1772
71. Janssen JWG, Buschle M, Layton M, et al. (1989) Clonal analysis of myelodysplastic syndromes: Evidence of multipotent stem cell origin. Blood 73: 248-254
72. Jensen PD, Jensen IM, Ellegaard J (1992) Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol 80: 121-124
73. Jin JY, Tooze JA, Marsh JCW, et al. (1996) Myelodysplasia following aplastic anaemia/paroxismal nocturnal after treatment with immunosupresion and G-CSF. Evidence for the emergence of a separate done. Br J Haematol 89: 510-512
74. Juneja SK, Imbert M, Jouault H, et al. (1983) Hematological features of primary myelodysplastic syndromes (PMDS) at initial presentation: a study of 118 cases. J Clin Pathol 36: 1129-1135
75. Kaneko H, Hoorike S, Taniwaki M, et al. (1996) Microsatellite instability is an early genetic event in myelodysplastic syndrome but it is infrequent and not associated with TGF-beta receptor type-II gene mutation. Leukemia 10: 1696-1699
76. Kerkhofs H, Hermans J, Haak HL, et al. (1987) Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br J Haematol 65: 73-81
77. Kernan NA, Bartsch G, Ash RC, et al. (1993) Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 328: 593-599
78. Kibbelaar RE, van Kamp H, Dreef EJ, et al. (1992) Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes. Blood 79: 1823-1828
79. Kouides A, Bennett JM (1996) Morphology and classification of the myelodysplastic syndromes and their pathologic variants. Semin Hematol 33: 95-110
80. List AP, Heaton R, Glinsmann-Gibson B, et al. (1994) Cytokine-like stimulation of multipotent and erythroid progenitor growth by WR-2771 and WR-1065 Blood 148 [Suppl 1]: 571a
81. List AF, Heaton R, Glinsmann-Gibson B, et al. (1995) Amifostine is a novel stimulant of bone marrow progenitor growth in myelodysplastic syndromes Blood 86 [Suppl 1]: 335a
82. List A, Capizzi R, Heaton R, et al. (1997) Promotion of multilineage hematopoiesis in patients with myelodysplastic syndrome: a phase I/II clinical trial with amifostine Leuk Res 21 [Suppl 1]: 47a
83. Mangi MH, Mufti GJ (1992) Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies. Blood 79: 198-205
84. Maschek H, Gutzmer R, Choritz H, et al. (1994) Life expectancy in primary myelodyspalstic syndromes: a prognostic score based upon histopathology from bone marrow biopsies in 569 patients. Eur J Haematol 53: 280-287
85. Mele A, Szldo M, Visani G, et al. (1994) Hair dye use and other risk factors for leulemia and pre-leukemia: a case-control study. Am J Epidemiol 139: 609-619
86. Michaux JL, Martiat P (1993) Chronic myelomonocytic leukaemia (CMML)- A myelodysplastic or myeloproliferative syndrome? Leuk Lymphoma 9: 35-41
87. Michels SD, McKenna RW, Arthur DC, et al. (1985) Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphological study of 65 cases. Blood 65: 1364-1372
88. Mills EN, Hayes RB, Fishman CL, et al. (1994) RAS mutations in chinese patients with benzene-associated and de nova acute leukemia Blood 84 [Suppl 1]: 47a
89. Molldrem J, Stetler-Stevenson M, Mavroudis D, et al. (1996) Antithymocyte globulin abrogates cytopenias in patients with myelodysplastic syndrome Blood 88 [Suppl 1]: 1804a
90. Morel P, Hebbar M, Lai JL, et al. (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 7: 1315-1323
91. Morel P, Declercq C, Hebbar M, et al. (1996) Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques. Br J Haematol 94: 116-119
92. Morosetti R, Koeffler HP (1996) Differentiation therapy in myelodysplastic syndromes. Semin Hematol 33: 236-245
93. Mufti GJ, Stevens JR, Oscier DG, et al. (1985) Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 59: 425-433
94. Nand S, Sosman J, Godwin JE, et al. (1994) A phase I/II study of sequential inteleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes. Blood 83: 357-360
95. Negrin RS, Stein R, Vardiman J, et al. (1993) Tretament of anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 82: 737-743
96. Negrin RS, Stein R, Doherty K, et al. (1996) Maintenace treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo sinergy. Blood 87: 4076-4081
97. Nemunaitis J, Rosenfeld C, Getty L, et al. (1995) Pentoxifyiline and ciprofloxacin in patients with myelodysplastic syndrome. Am J Clin Oncol 18: 189-193
98. Nisse C, Lorthois C, Dorp V, et al. (1995) Exposure to occupational and environmental factors in myelodysplastic syndromes. Preliminary results of a casa-control study. Leukemia 9: 693-699
99. Oguma S, Yoshida Y, Uchino H, et al. (1995) Clinical characteristics on Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases. Leuk Res 19: 219-225
100. Ohmori M, Ohmori S, Ueda Y, et al. (1990) Myelodysplastic syndrome (MDS)-associated inhibitory activity on haemopoietic progenitor cells. Br J Haematol 74: 179-184
101. Ohmori M, Ohmori S, Ueda Y, et al. (1991) Ineffective hematopoiesis in the myelodysplastic syndromes (MDS) as studied by daily in situ observation of colony-cluster formation. Int J Cell Cloning 9: 521-530
102. Ohmori S, Ohmori M, Yamagishi M, et al. (1993) MDS-macrophage derived inhibitory activity on myelopoiesis of MDS abnormal clones. Br J Haematol 83: 388-391
103. Omoto E, Deguchi S, Takaba S, et al. (1996) Low-dose melphalan for treatment of high-risk nyelodysplastic syndromes. Leukemia 10: 609-614
104. Orazi A, Cattoretti G, Solino D, et al. (1993) Therapy-related myelodysplastic syndromes: FAB classification, bone marrow histology, and immnunohistology in the prognostic assessment. Leukemia 7: 838-847
105. Paquette RL, Landau EM, Pierre RV, et al. (1993) N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 82: 590-599
106. Park DJ, Koeffler HP (1996) Therapy-related myelodysplastic syndromes. Semin Hematol 33: 256-273
107. Parker JE, Cullis J, Mijovic A, et al. (1997) Idarubicin, fludarabine, cytarabine and G-CSF (FLAG-IDA) for the treatment of high-risk MDS or AML Leuk Res 21 [Suppl 1]: 45a
108. Passmore SJ, Hann IM, Stiller CA, et al. 1995) Pediatric myelodysplasia: a study of 68 chidren and a new prognostic scoring system. Blood 85: 1742-1750
109. Pedersen-Bjergaard J, Philip P, Larsen SO, et al. (1990) Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 76: 1083-1091
110. Pedersen-Bjergaard J, Philip P, Larsen SO, et al. (1993) Therapyrelated myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated for malignant disease in the Copenhagen series. Leukemia 7: 1956-1986
111. Pedersen-Bjergaard J, Rowley JD (1994) The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may co0ntribute differently to malignant transformation. Blood 83: 2780-2786
112. Pedersen-Bjergaard J, Pedersen M, Roulston D, et al. (1995) Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 86: 3542-3552
113. Pomeroy C, Oken M, Rydell RE, et al. (1991) Infection in myelodysplastic syndromes. Am J Med 90: 338-344
114. Preisler HD, Raza A, Barcos M, et al. (1986) High-dose cytosine arabinoside in the treatment of preleukemic disorders: a Leukemia Intergroup study. Am J Hematol 23: 131-134
115. Ramakrishnan N, Catravas GN (1992) N-(2-mercaptoethyl-)-l,3-propenediamine (WR-1065) protects thymocytes from programmed cell death. J Immunol 148: 1817-1821
116. Raskind WH, Tirumali N, Jacobson R, et al. (1984) Evidence for a multistep pathogenesis of a myelodysplastic syndrome. Blood 63: 1318-1323
117. Raymakers R, De Witte T, Loziasse J, et al. (1991) in vitro growth pattern and differentiation predict for progression of myelodysplastic syndromes to acute nonlymphocytic leukemia. Br J Haematol 78: 35-41
118. Raza A, Gezer S, Mundle S, et al. (1995) Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86: 268-276
119. Raza A, Mundle S, Shetty V (1996) Novel insight into the biology of myelodysplastic syndromes. Excessive apoptosis and the role of cytokines. Int J Hematol 63: 265-278
120. Raza A, Shetty V, Dar S, Mundle S, et al. (1997) Successful anticytokine based approach to treta myelodysplastic syndromes (MDS) Leuk Res 21 [Suppl 1]: 40a
121. Rios A, Caetty V, Dar S, Mundle S, et al. (1997) Successful anticytokine based approach to treta myelodysplastic syndromes (MDS). Leuk Res 21 Int J Hematol 63: 265-278
122. Rosati S, Anastasi J, Vardiman J (1996) Recurring diagnostic problems in the pathology of the myelodysplastic syndromes. Semin Hematol 33: 111-126
123. Rosati S, Mick R, Xu F, et al. (1996) Refractory cytopenia with multilineage dysplasia: further characterization of an "unclassifiable" myelodysplastic syndrome. Leukemia 10: 20-26
124. Rosenbloom B, Schreck R, Koeffler P (1992) Therapy related myelodysplastic syndromes. Hematol Oncol Clin North Am 6: 707-722
125. Rothman N, Haas R, Hayes RB, et al. (1995) Benzene induces geneduplicating but not gene-inactivating mutations at the glycophorin A locus in exposed humans. Proc Natl Acad Sci USA 92: 4069-4073
126. Rowley JD, Golomb H, Vardiman J (1977) Nonrandom chromosomal abnormalities in acute non-lymphocytic leukemia in patients treated for Hodgkin's disease and non-Hodgkin's lymphomas. Blood 50: 759-770
127. Runde V, Aul C, Eberg A, Grabenhorst U, Schneider W (1995) Sequential administration of recombinant human granulocyte colny-stimulating factor and human erythropoietin for treatment of myelodysplastic syndromes. Eur J Haematol 54: 39-45
128. Runde V, De Witte T, Gratwohl A, et al. (1995) Allogeneic bone marrow transplantation (BMT) for myelodysplastic syndromes (MDS) or leukemia following MDS (sAML): a survey for the working party on chronic leukemia of the EBMTG Bone Marrow Transplant 15 [Suppl 2) : 16a
129. San Miguel JF, Sanz GF, Vallespi T, Sanz MA (1996) Myelodysplastic syndromes. Crit Rev Oncol Hematol 23: 57-93
130. Sanz GF, Sanz MA, Vallespi T, et al. (1989) Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74: 395-408
131. Sanz GF, Sanz MA, Vallespi T, et al. (1990) Two types of acquire idiopathic sideroblastic anaemia. Br J Haematol 75: 633-634
132. Sanz GF, Sanz MA (1992) Prognostic factors in myelodysplastc syndromes. Leuk Res 16: 77-86
133. Schuster MW, Larson RA, Thompson JA, et al. (1990) Granulocyte-macrophage colony-stimulating factor (GM-CSF) for myelodysplastic syndromes (MDS): Results of a multicenter randomized controlled trial. Blood 76 [Suppl 1]: 18a
134. Sepherd JD, Fung HC, Forrest DE, et al. (1997) Allogeneic bone marrow transplantation for adults with primary myelodysplastic syndromes: evaluation of prognostic factors. Leuk Res 21 [Suppl 1]: 52a
135. Shannon KM, O'Connell P, Martin Pa, et al. (1994) Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 330: 597-601
136. Sierra J, Carreras E, Rozman C, et al. (1997) Bone marrow transplantation for myelodysplasia: the IBMTR data. Leuk Res 21 [Suppl 1]: 51a
137. Socié G, Mary JY, Degramont A, et al. (1996) Paroxismal nocturnal hemoglobinuria -long-term follow-up and prognostic factors. Lancet 348: 573-577
138. Sultan C, Sigaux F, Imbert M, et al. (1981) Acute myelodysplasia with myelofibrosis: a report of eight cases. Br J Haematol 49: 11-16
139. Sutton L, Chastang C, Ribaud P, et al. (1996) Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients. Blood 88: 358-365.
140. Tefferi A, Thibodeau SN, Solberg Jr LA (1990) Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphism. Blood 75: 1770-1773
141. Third MIC Cooperative Study Group (1988) Recommendations for a morphologic, immunologic and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. Report of the workshop held in Scottsdale, Arizona, USA, on February 23-25, 1987. Cancer Genet Cytogenet 32: 1-10
142. Toyama K, Ohyashiki K, Yoshida Y, et al. (1993) Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 7: 499-508
143. Tricot G, Boogaerts MA, De Woif-Peeters C, et al. (1985) The myelodisplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations. Br J Haematol 59: 659-670
144. Tricot G, Vlietinck R, Boogaerts MA, et al. (1985) Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. Br J Haematol 60: 19-32
145. Tsukamoto N, Morita K, Maehara T, et al. (1993) Clonality in myelodysplastic syndromes: demonstration of pluripotent stem cell origin using X-linked restriction fragment length polymorphisms. Br J Haematol 83: 589-594
146. Van Den Berghe H, Vermaelen K, Mecucci C, et al. (1985) The 5q-anomaly. Cancer Genet Cytogenet 17: 189-255
147. Van der Weide M, Sizoo W, Nauta JJP, et al. (1988) Myelodysplastic syndromes: analysis of clinical and prognostic features in 96 patients. Eur J Haematol 41: 115-122
148. Vardiman J, Golomb H, Rowley J, et al. (1978) Acute non-lymphocytic leukemia in malignant lymphoma: a morphologic study. Cancer 42: 229-242
149. Varela BL, Chuang C, Woll JE, et al. (1985) Modifications in the classification of primary myelodysplastic syndromes. Hematol Oncol 3: 55-63
150. Wattel E, Lai JL, Hebbar M, et al. (1993) De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features? Leuk Res 17: 921-926
151. Wattel E, Hecquet B, Grahek D, et al. (1993) Long term survivors in myelodysplastic syndromes: a report on 63 cases and comparison with short and intermediate survivors. Leuk Res 17: 733-739
152. Wattel E, Preudhomme C, Hecquet B, et al. (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84: 3148-3157
153. Wattel E, Guerci A, Hecquet B, et al. (1996) A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytiv leukemia. Blood 88: 2480-2487
154. Wattel E, Solary E, Caillot D, et al. (1997) Autologous bone marrow (ABMT) or peripheral blood stem cell (ABSCT) transplantation after intensive chemotherapy in myelodysplastic syndromes (MDS) Leuk Res 21 [Suppl 1]: 52a
155. Weisdorf DJ, Oken MM, Johnson GJ, et al. (1983) Chronic myelodysplastic syndrome: short survival with or without evolution to acute leukaemia. Br J Haematol 55: 691-700
156. West RR, Stafford DA, Farrow A, et al. (1995) Occupational and environmental exposures and myelodysplasia: a case-control study. Leuk Res 19: 127-139
157. Wijermans PW, Krulder JW, Huijgens PC, et al. (1997) Continuous infusion of low-dose 5-Aza-2'-eoxyxytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia: 11: 1-5
158. Willman CL, Sever CE, Pallavicini MG, et al. (1993) Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 259: 968-971
159. White AD, Culligan DJ, Hoy TG, et al. (1992) Extended cytogenetic follow-up of patients with myelodysplastic syndrome. Br J Haematol 81: 499-502
160. Worsley A, Oscier DG, Stevens J, et al. (1988) Prognostic features of chronic myelomonocytic leukaemia:a modified Bournemouth score gives the best prediction of survival Br J Haematol 68: 17-21
161. Yin SN, Hayes RB, Linet MS, et al. (1996) An expanded cohort study of cancer among benzene-exposed workers in China. Environ Health Perspect 104: 1339-1341
162. Yoshida Y (1993) Hipothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndromes. Leukemia 7: 144-146
163. Yoshida Y, Anzai N, Kawabata H (1996) Apoptosis in normal and neoplastic hematopoiesis. Crit Rev Oncol Hematol 24: 185-211
164. Yunis JJ, Lobell M, Arnesen MA et al. (1988) Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndromes and acute myelogenous leukaemia. Br J Haematol 68: 189-194